Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554396 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Phase 2 study of Presbyopia, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02554396 is a Phase 2 study of Presbyopia that has completed, run by LENZ Therapeutics. The registered enrollment target is 20 participants, below the 270-participant average among 38 other Presbyopia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02554396, a Phase 2 study of Presbyopia, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision acuity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PRX-100
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554396
The ClinicalTrials.gov registry entry for NCT02554396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 38 other Presbyopia trials with a reported enrollment target (93% lower). The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02554396 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02554396 about?
NCT02554396 is a clinical study titled "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia". This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision a...
What is the current status of trial NCT02554396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-09. Estimated completion is 2015-11.
What conditions does trial NCT02554396 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT02554396?
The interventions under investigation include: Placebo (DRUG), PRX-100 (DRUG).
Who is sponsoring clinical trial NCT02554396?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02554396 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
COMPLETED · Phase 2
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Comfort and Vision With TOTAL30 Multifocal Lenses
RECRUITING
-
North American Comfilcon A Clinical Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.